The global contrast enhanced ultrasound market size was valued at USD 2.19 billion in 2025 and is projected to grow from USD 2.30 billion in 2026 to USD 3.44 billion by 2034, registering a CAGR of 5.14% during the forecast period from 2026 to 2034. North America dominated the contrast enhanced ultrasound market with a market share of 39.5% in 2025.
The introduction of ultrasonic contrast medium to regular medical sonography is called contrast-enhanced ultrasonography (CEUS). Ultrasound contrast agents rely on how sound waves are reflected from material interfaces. This could be the surface of an air bubble or something more complicated. Gas-filled microbubbles are delivered intravenously to the systemic circulation in a commercially available contrast medium.
Download a Free Sample To learn more about this report,
Dedicated Contrast Delivery Systems Moving Into Clinical CEUS Workflows
The need for more consistent contrast administration is bringing dedicated delivery systems into the Contrast-Enhanced Ultrasound Market. This transition is moving CEUS workflows beyond manual injection toward standardized delivery, with Bracco’s VueJect receiving U.S. FDA 510(k) clearance on August 3, 2026, under device number K262115 and Health Canada Medical Device License No. 115637. VueJect also enables continuous administration of ultrasound contrast agents during cardiac imaging, helping reduce operator variability and support more consistent enhancement across examinations.
CEUS Expanding Beyond Traditional Liver and Cardiac Imaging
The ability of CEUS to provide real-time microvascular perfusion information without ionizing radiation is extending its use into breast and other superficial-organ imaging applications. This shift is becoming more clinically structured, with a 2026 breast CEUS consensus developed by an expert panel comprising 52 listed authors and covering acquisition methods, qualitative and quantitative enhancement analysis, interpretation, and standardized reporting. The same consensus notes that breast CEUS has already been used in clinical practice for nearly two decades, showing that broader applications are moving from experimental use toward more formalized diagnostic workflows.
Radiation-Free Imaging Demand and Cost-Effective Diagnostics Drive Market Growth
Higher clinical preference for radiation-free imaging supports CEUS demand because ultrasound does not use ionizing radiation, unlike CT-based examinations. A clinical study of 146 focal liver lesions found that CEUS alone classified 89.0% as benign or malignant and provided specific lesion identification in 80.8% of cases. Repeated liver-lesion surveillance and follow-up imaging therefore provide practical applications where CEUS can reduce reliance on additional CT examinations and associated radiation exposure. Broader use of radiation-free diagnostic pathways consequently strengthens demand for ultrasound contrast agents, CEUS-capable systems, and related imaging services.
Greater pressure to control diagnostic costs increases interest in CEUS when clinicians can characterize lesions without immediately moving patients to CT or MRI. A multicenter study covering 575 focal liver lesions found that CEUS correctly differentiated benign from malignant lesions in 97.2% of cases and generated savings of about €162 per patient for the national health service compared with the conventional diagnostic pathway. Another prospective study of 459 patients found CEUS-based evaluation costs were about 4% lower than CT and substantially lower than MRI for incidental focal liver lesions.
Limited Contrast Agent Approvals and Low Clinical Awareness Restrain Market Expansion
Limited approval of ultrasound contrast agents across countries and clinical indications restricts where CEUS can be routinely used. Hospitals may avoid expanding CEUS programs when approved agents, reimbursement pathways, or indication-specific guidance remain unavailable. This regulatory and availability gap slows clinical adoption and limits broader expansion of the contrast enhanced ultrasound market.
Limited familiarity with contrast administration, image acquisition, and CEUS interpretation reduces confidence among clinicians who primarily rely on CT, MRI, or conventional ultrasound. Hospitals may need additional training, protocol development, and multidisciplinary coordination before CEUS becomes part of routine diagnostic workflows. This knowledge gap delays implementation and restricts adoption outside experienced imaging centers.
AI-Assisted CEUS Quantification and Theranostic Applications Create New Growth Opportunities
Ultrasound manufacturers, imaging-software developers, and contrast-agent companies can benefit from automated perfusion analysis, lesion quantification, and standardized CEUS reporting. Bracco’s VueBox already quantifies parameters such as wash-in rate, peak enhancement, rise time, time-to-peak, and area-under-the-curve from DCE-US clips, while its current platform supports cross-platform analysis through calibration files for major ultrasound systems.
Contrast-agent developers, biotechnology companies, pharmaceutical firms, and ultrasound manufacturers can benefit as microbubbles move beyond imaging toward targeted therapeutic delivery. A 2026 clinical trial evaluated ultrasound combined with microbubbles in invasive breast cancer, while another 2026 study used FDA-approved microbubbles with a clinical ultrasound scanner to investigate enhanced drug delivery in hepatocellular carcinoma.
Reimbursement and Cost Pressures and Complex Clinical Workflows Hinders Growth
CEUS providers must account for contrast agents, compatible imaging software, and the staff time needed to complete each examination. Payment may not cover these costs consistently across care settings, making hospitals cautious about expanding CEUS services. The resulting uncertainty can slow equipment purchases and limit demand for suppliers. The 2026 U.S. Medicare outpatient payment for certain noncardiac CEUS procedures rose to $243.77, illustrating how reimbursement levels remain a practical consideration for providers.
CEUS requires intravenous access, timed image capture, and coordination between imaging and clinical staff. These steps can make appointments harder to schedule and reduce the number of examinations a department can perform each day. Companies may therefore face longer sales cycles as hospitals assess whether they have enough staff and capacity to run a CEUS service. A published liver CEUS implementation report noted that examinations required two people and additional scheduling time.
The equipment segment dominated the contrast enhanced ultrasound market with a market share of 61.8% in 2025, supported by widespread use of advanced ultrasound systems for liver imaging, cardiac assessment, vascular evaluation, and other diagnostic procedures. Integration of contrast-specific imaging modes and improved image-processing capabilities continues to strengthen adoption across clinical settings.
The contrast agent segment is expected to grow at the fastest CAGR of 7.89% during the forecast period 2026–2034, supported by increasing use of microbubble-based agents to improve lesion characterization, blood-flow visualization, and diagnostic confidence during ultrasound examinations.
Request Customizationto receive a tailored report.
The non-targeted segment dominated the contrast enhanced ultrasound market with a market share of 72.6% in 2025, supported by its established use in routine vascular and organ imaging where microbubbles circulate through the bloodstream without binding to specific molecular targets. Its broad clinical applicability continues to support strong adoption.
The targeted segment is expected to grow at the fastest CAGR of 8.31% during the forecast period 2026–2034, supported by ongoing development of molecular imaging approaches designed to identify specific biomarkers and improve disease characterization.
The hospitals segment dominated the contrast enhanced ultrasound market with a market share of 56.7% in 2025, supported by higher patient volumes, availability of advanced imaging systems, and greater use of contrast-enhanced ultrasound across radiology, cardiology, oncology, and emergency departments. Access to trained specialists and integrated diagnostic infrastructure further supports its leading position.
The ambulatory diagnostic centers segment is expected to grow at the fastest CAGR of 7.91% during the forecast period 2026–2034, supported by demand for outpatient imaging, faster diagnostic workflows, and wider access to non-invasive ultrasound procedures. Clinics remain important for routine diagnostic assessments and follow-up imaging where compact ultrasound systems and shorter examination times are beneficial.
Speak to an Analystto discuss market opportunities.
The North America contrast enhanced ultrasound market accounted for the largest regional share of 39.5% in 2025. Regional strength is supported by advanced diagnostic imaging infrastructure, broad access to ultrasound systems, and established hospital-based imaging services.
The U.S. contrast enhanced ultrasound market is supported by the Census Bureau’s projection that one in every five Americans will be of retirement age by 2030, expanding the older patient population that may require diagnostic imaging for liver, cardiac, vascular, and other age-related conditions.
The Canada contrast enhanced ultrasound market is being shaped by Statistics Canada’s projection that the population aged 65 and older will reach about 9.4 million by 2030, compared with about 8.1 million in 2025. The population aged 85 and older is also projected to increase rapidly between 2031 and 2050, adding pressure on healthcare and diagnostic services.
Unlock Regional Insightsto access country-level data, & regional trends.
The Europe contrast enhanced ultrasound market is expected to register the fastest regional CAGR of 8.12% during the forecast period 2026–2034. Market development is being shaped by broader use of non-invasive diagnostic techniques and greater emphasis on early disease detection.
The U.K. contrast enhanced ultrasound market is supported by England’s National Cancer Plan, which aims for three out of four people diagnosed with cancer in 2035 to be cancer-free or living well five years later. The plan also targets at least a 20-percentage-point increase in cancers diagnosed at stages 1 and 2 by 2035 compared with 2019, strengthening the need for earlier and more accessible diagnostic imaging.
The Germany contrast enhanced ultrasound market is being influenced by demographic change, with the Federal Statistical Office projecting the population aged 67 and older to reach at least 20.5 million by the end of the 2030s, compared with 16.7 million in 2024. The population aged 67–79 is also projected to reach around 14 million by 2037, expanding the patient group requiring imaging for chronic and age-related conditions.
The Asia Pacific contrast enhanced ultrasound market accounted for a market share of 22.6% in 2025 and is expected to grow at a CAGR of 7.68% during the forecast period 2026–2034. Regional activity is supported by healthcare infrastructure development, wider access to advanced imaging technologies, and expansion of hospital diagnostic capacity.
The Japan contrast enhanced ultrasound market is being shaped by the Ministry of Health, Labour and Welfare’s cancer-care planning toward 2040, when total cancer cases are expected to remain broadly stable or increase slightly while cases among people aged 85 and older increase. Japan’s regional healthcare strategy also anticipates continued expansion of the 85-and-older population toward 2040, increasing demand for sustainable diagnostic services.
The China contrast enhanced ultrasound market is supported by the Cancer Prevention and Control Action Plan, which targets an overall five-year cancer survival rate of 46.6% by 2030 and stronger cancer-screening and early-diagnosis capabilities. China also targets an early-diagnosis rate of at least 55% for key cancers in high-incidence areas by 2030, reinforcing the need for technologies used to characterize lesions and monitor disease.
The India contrast enhanced ultrasound market is supported by projections that the country could see around 2 million new cancer cases annually by 2030. Tata Memorial Centre and the National Cancer Grid are also expanding regional cancer-care and diagnostic capabilities as the country prepares for a higher future cancer burden.
The contrast enhanced ultrasound market competitive landscape is moderately consolidated, with competition comprising global diagnostic imaging companies, ultrasound system manufacturers, contrast-agent developers, and specialized medical imaging firms serving radiology, cardiology, oncology, and vascular applications. Key players such as GE HealthCare, Siemens Healthineers AG, Bracco Diagnostics Inc., Lantheus Medical Imaging, Inc., and Shenzhen Mindray Bio-Medical Electronics Co. Ltd. collectively are estimated to account for approximately 55–60% of the global contrast enhanced ultrasound market share.
Established players compete primarily on imaging quality, contrast-agent compatibility, clinical validation, regulatory approvals, software capabilities, installed equipment base, and hospital relationships, while emerging and regional players in the contrast enhanced ultrasound market ecosystem compete through portable systems, application-specific imaging solutions, competitive pricing, workflow-focused software, localized support, and faster customization for specialized diagnostic requirements.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Germany Surgical Equipment Market Size, Share and Forecast to 2034
Europe Surgical Equipment Market Size, Top Share and Forecast to 2034
Biofeedback Instrument Market Size, Share, Growth, Analysis, 2034
Cardiac Assist Devices Market Size, Share, Growth, 2034
Radiosurgery Market Size, Share, Growth, Analysis, Report, 2034
Interventional Cardiology Devices Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com